Quick Answer
Beam Therapeutics Inc. reported Total Revenue of $139.74 million for fiscal year 2025.
Beam Therapeutics Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $139.74M +120.0% |
$63.52M -83.2% |
$377.71M +520.0% |
$60.92M +17.5% |
$51.84M +215916.7% |
$24.0K +33.3% |
| Revenue (ASC 606) | $139.74M +120.0% |
$63.52M -83.2% |
$377.71M +520.0% |
$60.92M +17.5% |
$51.84M +215916.7% |
$24.0K +33.3% |
| Net Income | -$79.99M +78.8% |
-$376.74M -184.3% |
-$132.53M +54.2% |
-$289.09M +22.0% |
-$370.64M -90.5% |
-$194.59M -148.4% |
| Diluted EPS | -$0.81 +82.3% |
-$4.58 -166.3% |
-$1.72 +58.4% |
-$4.13 +28.4% |
-$5.77 -37.7% |
-$4.19 +70.2% |
| Total Assets | $1.48B +34.2% |
$1.10B -24.4% |
$1.46B +8.8% |
$1.34B -9.0% |
$1.47B +226.4% |
$451.68M +189.4% |
| Cash and Equivalents | $294.94M +4.6% |
$281.97M -35.3% |
$435.89M +87.3% |
$232.77M -58.4% |
$559.99M +245.3% |
$162.17M +335.7% |
| Stockholders Equity | $1.24B +68.8% |
$733.54M -25.2% |
$981.33M +33.8% |
$733.47M -11.3% |
$826.74M +236.7% |
$245.56M +222.1% |
| R&D Expense | $409.62M +11.4% |
$367.56M -16.0% |
$437.38M +40.4% |
$311.59M -19.5% |
$387.09M +275.2% |
$103.18M +88.9% |
| Operating Income | -$383.69M +7.7% |
-$415.57M -135.5% |
-$176.49M +47.9% |
-$338.48M +13.8% |
-$392.46M -195.6% |
-$132.76M -76.7% |
| Shares Outstanding | 101.75M +21.7% |
83.63M +2.5% |
81.63M +14.5% |
71.28M +4.2% |
68.39M +19.4% |
57.25M +681.5% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $9.70M | -32.0% | +14.6% |
| Revenue (ASC 606) | September 30, 2025 | $9.70M | -32.0% | +14.6% |
| Net Income | September 30, 2025 | -$112.73M | -16.6% | -10.2% |
| Diluted EPS | September 30, 2025 | -$1.10 | +6.0% | -10.0% |
| Total Assets | September 30, 2025 | $1.31B | +11.9% | -5.8% |
| Cash and Equivalents | September 30, 2025 | $267.96M | +16.4% | -5.0% |
| Stockholders Equity | September 30, 2025 | $966.00M | +22.1% | -7.7% |
| R&D Expense | September 30, 2025 | $109.77M | +16.5% | +7.9% |
| Operating Income | September 30, 2025 | -$126.81M | -19.1% | -5.5% |
| Shares Outstanding | September 30, 2025 | 101.36M | +22.8% | +0.6% |
- Beam Therapeutics Inc. reported Total Revenue of $139.74 million for fiscal year 2025.
- Beam Therapeutics Inc. showed an increase of +120.0% in Total Revenue compared to the prior fiscal year.
- Beam Therapeutics Inc. reported Revenue (ASC 606) of $139.74 million for fiscal year 2025.
- Beam Therapeutics Inc. showed an increase of +120.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Beam Therapeutics Inc. reported Net Income of -$79.99 million for fiscal year 2025.
- Beam Therapeutics Inc. showed an increase of +78.8% in Net Income compared to the prior fiscal year.
- Beam Therapeutics Inc. reported Diluted EPS of $0.81 per share (loss) for fiscal year 2025.
- Beam Therapeutics Inc. showed an increase of +82.3% in Diluted EPS compared to the prior fiscal year.
- Beam Therapeutics Inc. reported Total Assets of $1.48 billion for fiscal year 2025.
- Beam Therapeutics Inc. showed an increase of +34.2% in Total Assets compared to the prior fiscal year.
- Beam Therapeutics Inc. reported Cash and Equivalents of $294.94 million for fiscal year 2025.
- Beam Therapeutics Inc. showed an increase of +4.6% in Cash and Equivalents compared to the prior fiscal year.
- Beam Therapeutics Inc. reported Stockholders Equity of $1.24 billion for fiscal year 2025.
- Beam Therapeutics Inc. showed an increase of +68.8% in Stockholders Equity compared to the prior fiscal year.
- Beam Therapeutics Inc. reported R&D Expense of $409.62 million for fiscal year 2025.
- Beam Therapeutics Inc. showed an increase of +11.4% in R&D Expense compared to the prior fiscal year.
- Beam Therapeutics Inc. reported Operating Income of -$383.69 million for fiscal year 2025.
- Beam Therapeutics Inc. showed an increase of +7.7% in Operating Income compared to the prior fiscal year.
- Beam Therapeutics Inc. reported Shares Outstanding of 101.75 million shares for fiscal year 2025.
- Beam Therapeutics Inc. showed an increase of +21.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: